BIDMC Gets an 'A' for Patient Safety
Beth Israel Deaconess Medical Center has been honored with an ‘A’ Hospital Safety Score by The Leapfrog Group, an independent national nonprofit run by employers and other large purchasers of health benefits in the latest update to the Hospital Safety ScoreSM.
Hospital Safety Score assigns grades from A through F to U.S. hospitals based on preventable medical errors, injuries accidents, and infections. The score was compiled under the guidance of the nation’s leading experts on patient safety and is designed to give the public information they can use to protect themselves and their families.
“We are pleased to once again be recognized for our efforts to reduce preventable harm and medical errors,” says Ken Sands, MD, Senior Vice President of Health Care Quality at BIDMC. “It is an excellent benchmark as we continue along our road to eliminate preventable harm.”
“It's The Leapfrog Group's goal to give patients the information they need and deserve before even entering a hospital,” says Leah Binder, President and CEO of The Leapfrog Group. “We congratulate the hospitals that earned an 'A' and we look forward to the day when all hospitals in the U.S. will earn the highest scores for putting patient safety first.”
To see BIDMC’s scores as they compare nationally and locally, visit HospitalSafetyScore.org, which also provides information on how the public can protect themselves and loved ones during a hospital stay. You can also check your local hospital’s score on a free mobile app that is available at the website.
The Leapfrog Hospital Survey assesses hospital performance based on national performance measures of safety, quality, and resource utilization. These measures are of specific interest to healthcare purchasers and consumers, and cover a broad spectrum of hospital processes, outcomes, and structures in many areas of care. The measures also provide hospitals with the opportunity to benchmark the progress they are making in improving the care they deliver.
New Wound Care Center Opens at BID-Needham
Beth Israel Deaconess Hospital-Needham recently opened the doors to its new Center for Wound Care and Hyperbaric Medicine, sharing space with the new Joslin Center for Diabetes and Endocrinology.
“This is the first center of its kind in the area,” says John Giurini, DPM, Chief of the Division of Podiatry at Beth Israel Deaconess Medical Center and Co-Medical Director of BID-Needham’s Center for Wound Care and Hyperbaric Medicine.
“Sharing a new outpatient clinic creates a unique collaboration between specialists," Giurini adds, "making it easier for patients to receive wound care, specialized care for diabetes and other endocrine disorders, plus laboratory services all in one location.”
Hyperbaric oxygen therapy (HBOT) helps the body’s oxygen-dependent, wound-healing mechanisms function more efficiently. While enclosed in a chamber at greater-than-normal atmospheric pressure, patients breathe pure oxygen, saturating their blood plasma and allowing it to carry 15 to 20 times the normal amount of healing oxygen to the body’s tissues. Up to 18 percent of wounds may benefit from HBOT treatment.
HBOT can help reduce swelling, fight infections, build new blood vessels, produce healthy tissue and improve circulation. Studies show that HBOT speeds the healing of many types of wounds, including those resulting from complications of diabetes. HBOT can also reduce the risk of wound-related amputations, especially for patients with diabetes.
Led by doctors and nurses specially trained in hyperbaric medicine and wound care, all of the center’s physicians are currently affiliated with BID-Needham and BIDMC in the areas of emergency medicine, podiatry and vascular surgery. In addition to HBOT therapy, staff provides a wide range of advanced wound-care treatments and individualized care plans that address the underlying causes of a wound.
Through the affiliation with Joslin Diabetes Center, specialists also provide treatment for adult diabetes and endocrinology, nutrition counseling and patient education, as well as comprehensive evaluation and treatment of endocrine disorders, including diabetes and thyroid, adrenal and pituitary diseases.
The center is located at 145 Rosemary Street, Suite D, in Needham, directly behind the Needham Public Library.
Learn more »
Make an Appointment
Center for Wound Care and Hyperbaric Medicine: 781-453-8500
Joslin Center for Diabetes and Endocrinology: 781-453-8525
Pier Paolo Pandolfi, MD, PhD, Named Director of BIDMC's Cancer Center
Internationally recognized scientist credited with curing acute promyelocytic leukemia
Pier Paolo Pandolfi, MD, PhD, a world-renowned researcher on the genetics and biology of cancer, has been named Director of the Cancer Center and the new Cancer Research Institute at Beth Israel Deaconess Medical Center.
Pandolfi (right), the 2011 recipient of one of the world’s most prestigious cancer research awards, is credited with curing acute promyelocytic leukemia (APL), a once deadly form of leukemia, and is at the center of some of the most promising breakthroughs in the race to prevent, treat and cure cancer.
“Dr. Pandolfi’s entire career has been motivated by a deep caring for the individual with cancer,” says Kevin Tabb, MD, President and CEO of BIDMC. “He has not only unlocked genetic secrets that led to a cure of APL, but he has also made several important discoveries and developed novel methodologies with hopeful implications for treating other cancers. Dr. Pandolfi is one of the true leaders in the field, and having him head our Cancer Center puts BIDMC in the center of a change in the way clinicians and scientists think about cancer.”
A prolific investigator who has published hundreds of scientific papers and received numerous awards, Pandolfi joined the BIDMC faculty in 2007 from the Memorial Sloan-Kettering Cancer Center in New York. He currently serves as Chief of BIDMC’s Division of Genetics in the Department of Medicine, Director of Research in the Cancer Center, and Director of the Cancer Genetics Program. He is also the George C. Reisman Professor of Medicine at Harvard Medical School.
“My mother and father passed away too young from cancer,” Pandolfi says. “I lost dear friends and colleagues to cancer. Cancer research is for me, in great part, a personal quest. My team shares my feelings and this is why we are so committed and driven to find a cure, and to find it soon.
“While I personally experienced the deep sorrow and the suffering that cancer brings in our lives, in our families, I also know that cancer can be cured. We cured APL, so I know that it can be done. This awareness makes us even more determined,” he adds. “As we better understand the biology and genetics of cancer, and as technical tools improve, the opportunities for improvements in early detection, diagnosis and treatment of cancer have never been better. Our challenge is to translate these into cancer care in the years to come.”
“We stand at a crossroads of challenge and opportunity in our fight against cancer,” says Jeffrey Flier, MD, Dean of Harvard Medical School. “We are extremely fortunate to have Dr. Pandolfi in this key leadership role at one of Harvard’s great teaching hospitals, and as an important member of the Harvard-wide cancer research community.”
In his new role, Pandolfi will work to promote excellence in all aspects of cancer care at BIDMC’s Leon V. & Marilyn L. Rosenberg Clinical Cancer Center, where multidisciplinary teams offer 21 specialty programs, such as those focusing on breast cancer, prostate cancer and biologic therapy.
“I look forward to further strengthening the links between research and clinical care,” says Pandolfi. “Our cancer clinicians here at BIDMC already offer the best in early diagnosis, leading edge treatments and personalized care plans. Patients and families know us for our highly individualized care and cherish the compassion and warmth, which characterizes all of Beth Israel Deaconess.”
Pandolfi will also head BIDMC’s newly launched Cancer Research Institute, which consolidates and strengthens research efforts within the Cancer Center, capitalizing on the unique expertise and creativity of BIDMC’s cancer investigators. Cancer research represents 35 percent of BIDMC’s research portfolio.
In 2011, Pandolfi was recognized with the Pezcoller Foundation-AACR (American Association for Cancer Research) International Award for Cancer Research. This prestigious honor, established in 1997, recognizes a scientist of international renown who has made a major scientific discovery in either basic or translational cancer research or whose ongoing work holds promise for progress in the field of cancer.
Pandolfi’s 1998 discovery of the genes that cause acute promyelocytic leukemia and subsequent work on mouse models of APL to develop effective combinatorial targeted treatments resulted in a cure for virtually all patients with this aggressive blood cancer.
Using a variety of engineered mouse lines to study the effects and interactions of genes linked to the formation of cancer, Pandolfi and a team of researchers at BIDMC have also developed a unique platform for discovery, the “Mouse Hospital,” where mice are genetically altered to replicate human cancers. This enables BIDMC investigators to conduct human clinical trials in parallel with genetically relevant mouse models to determine the efficacy of new treatments in later-stage cancers. This co-clinical methodology will speed the development and approval of new drugs and provide insights into the pathways by which individual cancers wreak havoc.
Most recently, Pandolfi’s revolutionary work has revealed that non-coding RNAs regulate basic biological processes such as growth and tumorigenesis, thus dispelling long-held beliefs that non-protein coding genes in the human genome were “junk.” This discovery has already sparked the development of new targeted drugs to treat disease in patients.
Above content provided by Beth Israel Deaconess Medical Center. For advice about your medical care, consult your doctor.
Posted November 2013